Cecinio Ronquillo, MD
Retina Specialist · Colorado Springs, CONPI 1679968580
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,345 of the $10,292 with a category attached, or 61.6%. Genentech, Inc. accounts for 66.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $7,058 and has fallen 94.4% since, to $394 in 2025.
Across 35 payments — averaging $294.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$7K
- Kyowa Kirin, Inc.$1K
- Genentech USA, Inc.$492
- Astellas Pharma US Inc$357
- Alimera Sciences, Inc.$255
- Alcon$212
- plus $867 from 8 others
Across 58 payments — averaging $2833.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin, Inc.$164K
What the payments were for
- Consulting fees$6,34562%
- Travel & lodging$1,49815%
- Food & beverage$2,44924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 3 | $6,846 |
| Kyowa Kirin, Inc. | 7 | $1,262 |
| Genentech USA, Inc. | 4 | $492 |
| Astellas Pharma US Inc | 4 | $357 |
| Alimera Sciences, Inc. | 2 | $255 |
| Alcon | 2 | $212 |
| Regeneron Healthcare Solutions, Inc. | 4 | $183 |
| Eyepoint US, Inc. | 2 | $175 |
| Apellis Pharmaceuticals, Inc. | 2 | $142 |
| Biogen | 1 | $133 |
| Novartis | 1 | $102 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $93 |
| AbbVie | 1 | $25 |
| Harrow Eye, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,292 in reported general payments places this provider in the 70th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 131 | $4,498 |
| Brimonidine Tartrate | 21 | $1,461 |
| Ciprofloxacin Hcl | 90 | $1,126 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $389 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Colorado Springs
- Adam MartidisColorado Springs$15K
- James LuuColorado Springs$11K
- Ramin SarrafizadehColorado Springs$6K
- Stanford TaylorColorado Springs$5K
- Mark ChittumColorado Springs$4K
- Amar ManninaColorado Springs$2K
- Jonathan WilliamsColorado Springs$367
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.